Novartis (NVS)

[Solantey]

Amarantus Bioscience's (AMBS) management has stated that it has a second orphan indication for its patented drug, MANF. It is believed to be in the field of diabetes and Novartis is rumored to be the potential development partner. It's interesting to note that Dr. Owen Garrick is on AMBS's board of advisors.


http://www.amarantus.com/about-us/board-of-advisors


Dr. Owen Garrick

Dr. Garrick joins Amarantus with over 20 years of pharmaceutical and biotechnology experience. He currently serves as the Chief Operating Officer at Bridge Clinical Research and is President of the American Medical Association Foundation. Prior to that, he was Director of Corporate Strategy and Business Development at McKesson Corporation. Dr. Garrick was Executive Director and Co-Head of Mergers & Acquisitions at Novartis Pharmaceuticals where he oversaw company acquisitions, hybrid equity/license rights deals, mature product divestments and venture investments in biotechnology companies. Prior to Novartis, Dr. Garrick was an associate at Goldman Sachs in New York. Dr. Garrick received his MD from Yale School of Medicine and earned his MBA from Wharton School of Business. He holds an AB from Princeton University, where he has served on the national fund raising board.